Seattle Genetics Inc.
Class Period: Oct 27, 2016 to Dec 23, 2016
Lead Plaintiff Deadline: Mar 13, 2017
Summary of Case:
A securities class action has been filed against Seattle Genetics Inc. (NASDAQ:SGEN) on behalf of purchasers of Seattle Genetics securities from October 27, 2016 through December 23, 2016. This case has been filed in the USDC - Washington (Western).
The Complaint alleges that throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) vadastuximab talirine, one of Seattle Genetics' products in development, presents a significant risk of fatal hepatotoxicity; (2) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia; and (3) as a result, defendants' public statements about Seattle Genetics' business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.